---
figid: PMC8540092__jpm-11-01032-g001
figtitle: Influence of Genetic Polymorphisms on Clinical Outcomes of Glatiramer Acetate
  in Multiple Sclerosis Patients
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
pmcid: PMC8540092
filename: jpm-11-01032-g001.jpg
figlink: /pmc/articles/PMC8540092/figure/jpm-11-01032-f001/
number: F1
caption: 'Mechanism of action of GA in treatment of multiple sclerosis. GA modulates
  the immune response and alters T-cell differentiation by competing with MBP in the
  major histocompatibility complex responsible for antigen presentation. Numbers represent
  the action site of genes with probable potential involvement in the pharmacokinetics
  and pharmacodynamics of GA therapy, patho-etiology of MS, apoptosis and neuroprotection,
  and CNS repair. 1. APCs: CD86, CCR5, CLEC16A; 2. MHC: HLA-DRB1, CTSS; 3. TCR: TRBC1;
  4. T-cell regulation: EOMES, PVT1, CCR5, PTPRT, UVRAG; 5. Pro-inflammatory pathway:
  ALOX5AP, IL12RB2, IL22RA2, IL1RL1; 6. MPB: MPB, CTSS; 7. T-cell migration: CCR5;
  8. CNS: MAGI2, RFLP3, SLAC1A4; * Other: Apoptosis mediatiors: CD95, ZAK. APC: antigen-presenting
  cells; BBB: blood–brain barrier; CNS: central nervous system.'
papertitle: Influence of Genetic Polymorphisms on Clinical Outcomes of Glatiramer
  Acetate in Multiple Sclerosis Patients.
reftext: María José Zarzuelo-Romero, et al. J Pers Med. 2021 Oct;11(10):1032.
year: '2021'
doi: 10.3390/jpm11101032
journal_title: Journal of Personalized Medicine
journal_nlm_ta: J Pers Med
publisher_name: MDPI
keywords: multiple sclerosis | glatiramer acetate | myelin basic protein | response
  | treatment | polymorphisms | pharmacogenetics | medicine personalized
automl_pathway: 0.9043323
figid_alias: PMC8540092__F1
figtype: Figure
redirect_from: /figures/PMC8540092__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8540092__jpm-11-01032-g001.html
  '@type': Dataset
  description: 'Mechanism of action of GA in treatment of multiple sclerosis. GA modulates
    the immune response and alters T-cell differentiation by competing with MBP in
    the major histocompatibility complex responsible for antigen presentation. Numbers
    represent the action site of genes with probable potential involvement in the
    pharmacokinetics and pharmacodynamics of GA therapy, patho-etiology of MS, apoptosis
    and neuroprotection, and CNS repair. 1. APCs: CD86, CCR5, CLEC16A; 2. MHC: HLA-DRB1,
    CTSS; 3. TCR: TRBC1; 4. T-cell regulation: EOMES, PVT1, CCR5, PTPRT, UVRAG; 5.
    Pro-inflammatory pathway: ALOX5AP, IL12RB2, IL22RA2, IL1RL1; 6. MPB: MPB, CTSS;
    7. T-cell migration: CCR5; 8. CNS: MAGI2, RFLP3, SLAC1A4; * Other: Apoptosis mediatiors:
    CD95, ZAK. APC: antigen-presenting cells; BBB: blood–brain barrier; CNS: central
    nervous system.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Tcr
  - Mhc
  - zip
  - dpp
  - gbb
  - put
  - mav
  - TRBV20OR9-2
  - TRA
  - TRB
  - TRD
  - TRG
  - HLA-C
  - IL4
  - IL10
  - TGFB1
  - TGFB2
  - TGFB3
---
